IDEAYA

Recent news mentioning IDEAYA

• 2026-09-01 — IDEAYA Biosciences Announces London Investor R&D Day and Participation in Upcoming September 2026 Investor Conferences
• 2026-08-31 — IDEAYA Biosciences Announces Successful FDA Type C Meeting for IDE849, DLL3 TOP1 ADC, on Phase 3 Registrational Trial Design for Potential Accelerated and Full Approval in Extensive Stage Small Cell Lung Cancer
• 2026-08-28 — IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
• 2026-08-19 — IDEAYA Biosciences Announces Clinical Collaboration with Genentech in MTAP-Deleted KRAS G12D-Mutant Pancreatic Cancer
• 2026-08-04 — IDEAYA Biosciences Reports Second Quarter 2026 Financial Results and Provides Business Update
• 2026-07-31 — IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
• 2026-07-27 — IDEAYA Biosciences Announces IDE892, a Potential Best-in-Class MTA-Cooperative PRMT5 Inhibitor, Initiates Part 2 Monotherapy Expansion in the Phase 1/2 Study in MTAP-Deleted Pancreatic and Lung Cancers

Appears alongside

• Nasdaq
• FDA
• IDE849
• DLL3
• TOP1
• ADC
• KRAS
• IDE892
• PRMT5

Browse the full archive →